Norsk
Foto: Oncoinvent
2017 has been a good year for Oncoinvent. The company has relocated and built new office and laboratory facilities, grown from four to twelve employees, and raised new capital. CEO at Oncoinvent, Jan A. Alfheim believes that this represents a significant milestone for the company and will enable further development of Radspherin®, a novel alpha-emitting radioactive microparticle designed for treatment of metastatic cancers in body cavities.
Oncoinvent ends the year in fashion by opening brand new laboratory and production facilities. Many interested investors came to tour the new facilities, observing an impressive lab with specialised infrastructure. Treating radioactivity, and circulating air in a facility that treats radioactive materials, calls for a particularly advanced ventilation system.
Laboratory With all Facilities
The idea of the new lab and research facility is to be able to contain the whole production line, from research to drug manufacturing, to one location. All this contained in an area of 581 m2.
Creating a modern lab with the capabilities to treat radioactive materials in an active and well populated part of Oslo demands very strict control. The production suites in the facility are constructed to be qualified for Good Manufacturing Practice (GMP) for production of Medical Product Candidates. Systems for purifying and monitoring air and water quality, as well as the removal of any potential radioactivity, have been installed to ensure the safety of the operators, population and the environment.
The Production and Research areas of the laboratory will facilitate both the development of the Radspherin program and other discovery projects of the Company.
A Weapon for Precision Medicine
Radspherin® has been shown to cause a significant reduction in tumor growth in preclinical studies and it is anticipated that the product can potentially treat several forms of metastatic cancer, primarily in peritoneal carcinomatosis originating from ovarian cancer. Oncoinvent is developing Radspherin® as a ready-to-use injectable product that seeks out cancer tumours and destroys them by emitting its radioactive content.
The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis, a rare type of cancer that occurs in the peritoneum, the thin layer of tissue that covers abdominal organs and surrounds the abdominal cavity. Additionally, Oncoinvent has lined up a collaboration with European and American clinical research centers for the clinical development Radspherin®.
Foto: Oncoinvent
Foto: Oncoinvent
Foto: Oncoinvent